Budget 2013: Personal income tax rebates for taxpayers

SINGAPORE: The government has introduced a slew of measures to help Singaporeans cope with the rising cost of living.

These measures include income tax rebates, extra GST voucher and Service & Conservancy Charges rebates.

Taxpayers who are 60 years and above will enjoy a higher income tax rebate of 50 per cent, capped at S$1,500.

Those who are below 60 years old will get a rebate of 30 per cent, which is also capped at S$1,500.

These measures were announced by Deputy Prime Minister in his Budget Statement on Monday.

Singaporeans will also get an extra one-off GST voucher on top of the permanent voucher.

The government will give rebates of one to three months for Service & Conservancy Charges.

One- and two-room HDB households will receive three months of rebates for 2013, while three- and four-room households will get two months of rebates.

The concessionary foreign domestic worker levy will be lowered for families with young children, elderly dependents and persons with disabilities.

The levy will be reduced from S$170 to S$120 per month.

- CNA/fa

Read More..

Suryanelli rape case: Hearing of bail pleas adjourned to March 4

KOCHI: The Kerala high court on Monday adjourned to March four the hearing of the bail pleas of 17 accused in the Suryanelli rape case allegedly involving Rajya Sabha Deputy Chairman P J Kurien.

A division bench comprising Justices K T Shankaran and M L Joseph Francis said the appeal and records about the case had not been received from the Supreme Court and it cannot proceed without perusing them, even though the accused wanted their pleas to be taken up today.

According to the accused, the apex court had not gone into the merits of the case and judgement was on technical grounds. The accused, who had been convicted and sentenced by the sessions court, are among the 35 acquitted by a division bench of the high court in 2005.

However, the Supreme Court had however recently set aside the acquittals and asked them to surrender before the special court hearing the case.

First accused Rajan and fifth accused Cherian are among those who have moved for bail maintaining there was no material against them to prove the charges.

Dharmarajan, the third accused, who had jumped bail, had recently been arrested from Karnataka and sent to jail. The high court had reduced his life term to five years. Following the Supreme Court judgement, Dharmarajan has to undergo the rest of his prison term.

The case relates to a 16-year-old girl who was abducted in 1996 and taken to to various places and sexually exploited.

Kurien was acquitted but the victim had recently named him as one of those who allegedly assaulted her in 1996.

The victim had also sent a letter to her advocate seeking to explore the possibility of filing a review plea in the Supreme Court for a fresh probe against Kurien, who according to the victim, had raped her at the Kumily guest house on February 9, 1996.

Kurien has maintained that he had been cleared of the charges by the apex court.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Oscars 2013: 'Argo' Wins Best Picture

"Argo" took home the top prize as best picture at the Oscars Sunday night, with first lady Michelle Obama announcing the winner from the White House.

"You directed a hell of a film," co-producer Grant Heslov told director and fellow producer Ben Affleck. "I couldn't be more proud of the film and more proud of our director."

Affleck was snubbed in the directing category but humbly accepted the best picture Oscar as one of the three producers on the film. George Clooney was the third.

Affleck thanked Steven Spielberg and the other best picture nominees and his wife Jennifer Garner for "working on our marriage."

"It's good, it's work," he said, adding, "but there's no one I'd rather work with."

For Full List of Winners

Acknowledging his last Oscar win, as a screenwriter for "Good Will Hunting," Affleck said, "I was really just a kid. I never thought I would be back here."

In the acting categories, Daniel Day-Lewis won the Oscar for best actor, being the first actor to three-peat in that category. As he accepted the award from Hollywood's greatest actress, Meryl Streep, he joked, "I had actually been committed to play Margaret Thatcher. ... Meryl was Stephen's first choice for Lincoln."

He also thanked his wife, Rebecca Miller, for "living with some very strange men," with each new role that he takes on.

"She's the versatile one in the family and she's been the perfect companion to all of them," he said.

Kevin Winter/Getty Images

Daniel Day-Lewis Gets Laughs With Oscars Speech Watch Video

Jennifer Lawrence won the award for best actress. She tripped on the stairs on her way to accepting her award but picked herself up and made her way to the stage, earning a standing ovation.

"You're just standing up because you feel bad that I fell and that's embarrassing," she said, before rattling off a list of thank-yous and leaving the stage looking slightly stunned.

Watch Jennifer Lawrence's Oscar Tumble

"Life of Pi," which had a total of 11 nominations, was another big winner of the night. Director Ang Lee took home the Oscar for best director over Steven Spielberg and David O. Russell.

"Thank you, movie god," Lee said, accepting his award.

As expected, the film took home the first technical awards of the night for cinematography and visual effects. "Life of Pi" also won for best original score.

The first big acting awards of the night went to Christoph Waltz and Anne Hathaway in the supporting actor categories.

In one of the biggest tossups, Waltz claimed the award for supporting actor for his role in "Django Unchained." It was his second Oscar for a Quentin Tarantino film; his first was for Tarantino's "Inglourious Basterds."

PHOTOS: Stars on the Red Carpet

As expected, Hathaway took home the award for best supporting actress for her role as Fantine in "Les Miserables."

"It came true," she said, launching into a breathy speech, in which she thanked the cast and crew, her team and her husband. "The greatest moment of my life was when you walked into it," she said.

Tarantino won the Oscar for best original screenplay for his slave revenge western "Django Unchained." He thanked his cast.

"I have to cast the right people," he said. "And boy this time did I do it."

Chris Terrio won the award for best adapted screenplay for "Argo," which also won for film editing.

For only the sixth time in Academy history, there was a tie at the Oscars. "Zero Dark Thirty" and "Skyfall" tied for sound editing.

See Other Ties in Academy History

Read More..

Indian PM calls for calm after deadly Hyderabad blasts

NEW DELHI: Indian Prime Minister Manmohan Singh on Sunday appealed for calm as he flew to Hyderabad and visited some of the 117 people wounded in twin bombings last week which killed 16 people.

Singh also visited the blast site in Dilsukh Nagar, where two bicycle bombs exploded within a few minutes of each other outside a cinema and near a bus stand on Thursday evening.

The prime minister met with some of the blast survivors and medical staff in two city hospitals and expressed his condolences.

"It is most important that in this hour of grief the people should maintain calm," he said.

"I am happy that the people of Hyderabad have refused to be provoked by this nefarious incident," the prime minister told reporters.

"I pray for the speedy recovery of those who have been injured, to those who have died I send my condolences to all the bereaved families," Singh added.

His spokesman Pankaj Pachauri told AFP Singh was scheduled to be briefed by N. Kiran Kumar Reddy, chief minister of the southern state of Andhra Pradesh, on the incident.

Hyderabad, one of the major hubs of India's booming software industry, is the capital of coastal Andhra Pradesh.

The premier has vowed to bring to justice the perpetrators of what he called a "dastardly" attack, the first major bombings in India since 2011.

His Congress Party-led government was criticised in parliament on Friday by the opposition, which said the bombings had exposed systemic security failures at a time when India is on heightened alert.

India's main opposition BJP party mocked the premier's one-day trip to Hyderabad saying the blasts were a result of the Indian government's failure to tackle terrorism.

"The prime minister's visit to Hyderabad is a non-event," BJP leader Balbir Punj told reporters in New Delhi.

"In fact, if he and his government had been sensitive to the issue of terrorism in this country... this attack would not have taken place," he said.

Andhra Pradesh Home Minister P. Sabita Indra Reddy has said investigators have found "vital clues" but gave no details.

Newspapers have pointed the finger at the Indian Mujahideen, a banned militant outfit which has claimed responsibility for previous attacks.

The fitting of the explosive devices to bicycles was similar to other attacks by the outfit, local media reports quoted investigators as saying.

The homegrown group has links to Lashkar-e-Taiba, the Pakistan-based militant outfit blamed for the 2008 Mumbai attacks that claimed 166 lives, according to Indian intelligence officials.

New Delhi has long accused its neighbour of aiding and abetting the militant groups who have carried out attacks on Indian soil -- a charge that Pakistan rejects.

- AFP/fa

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Iran won't go beyond nuclear obligations: envoy

TEHRAN: Iran said Saturday it will not go beyond its obligations nor accept anything outside its rights under the non-proliferation treaty, ahead of talks with major powers over its disputed nuclear drive.

"We will not accept anything beyond our obligations and will not accept anything less than our rights," said the Islamic republic's top nuclear negotiator, Saeed Jalili, quoted by ISNA news agency.

"Iran has fulfilled its NPT obligations as an active and committed member, therefore should gain all of its rights," Jalili said in an address to Iranian nuclear industry officials.

His remarks come ahead of a meeting between Iran and six world powers -- Britain, China, France, Russia, the United States and Germany -- in Kazakhstan on Tuesday.

The talks will be the first between the parties since three rounds of meetings in Moscow ended in stalemate in June last year.

The so-called P5+1 called on Iran to scale back on uranium enrichment, the process which used for power plant fuel and in higher purities needed for a nuclear weapon.

But they stopped short of offering Tehran substantial relief from UN Security Council and unilateral Western sanctions that last year began to cause major economic problems for the Gulf country.

Iran denies seeking atomic weapons but many in the international community suspect otherwise.

-AFP/fl

Read More..

Five cops suspended on rape allegations in Karnataka

CHIKMAGALUR (Karnataka): Five police personnel, including two women attached to Aldur police station in this district, were today placed under suspension following allegations by a woman that three policemen raped her while she was in their custody, police said.

Western Range IGP Pratap Reddy told reporters here that sub-inspector K R Shivakumar, constables Gururaj, K B Mahesh, woman constable Krithika and woman assistant sub-inspector Nandita Shetty have been suspended pending probe on the complaint filed by the victim.

The victim alleged that the three policemen sexually assaulted her on February 18 in Bangalore when they took her into custody in connection with a gold chain theft case.

The two women police personnel were present when the victim was taken into custody.

The woman and the policemen have been subjected to medical examination and the report is awaited, Reddy said.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Cyberattacks Bring Attention to Security Reform

Recent accusations of a large-scale cyber crime effort by the Chinese government left many wondering what immediate steps the president and Congress are taking to prevent these attacks from happening again.

On Wednesday, the White House released the administration's Strategy on Mitigating the Theft of U.S. Trade Secrets as a follow-up to the president's executive order. The strategy did not outwardly mention China, but it implied U.S. government awareness of the problem.

"We are taking a whole of government approach to stop the theft of trade secrets by foreign competitors or foreign governments by any means -- cyber or otherwise," U.S. Intellectual Property Enforcement Coordinator Victoria Espinel said in a White House statement.

As of now, the administration's strategy is the first direct step in addressing cybersecurity, but in order for change to happen Congress needs to be involved. So far, the Cyber Intelligence Sharing and Protection Act (CISPA) is the most notable Congressional legislation addressing the problem, despite its past controversy.

Last April, CISPA was introduced by House Intelligence Committee Chairman Mike Rogers, R-Mich., and Rep. Dutch Ruppersberger, D-Md. The act would allow private companies with consumer information to voluntarily share those details with the NSA and the DOD in order to combat cyber attacks.

Peter Parks/AFP/Getty Images

The companies would be protected from any liabilities if the information was somehow mishandled. This portion of the act sounded alarm bells for CISPA's opponents, like the ACLU, which worried that this provision would incentivize companies to share individuals' information with disregard.

CISPA passed in the House of Representatives, despite a veto threat from the White House stemming from similar privacy concerns. The bill then died in the Senate.

This year, CISPA was reintroduced the day after the State of the Union address during which the president declared an executive order targeting similar security concerns from a government standpoint.

In contrast to CISPA, the executive order would be initiated on the end of the government, and federal agencies would share relevant information regarding threats with private industries, rather than asking businesses to supply data details. All information shared by the government would be unclassified.

At the core of both the executive order and CISPA, U.S. businesses and the government would be encouraged to work together to combat cyber threats. However, each option would clearly take a different route to collaboration. The difference seems minimal, but has been the subject of legislative debates between the president and Congress for almost a year, until now.

"My response to the president's executive order is very positive," Ruppersberger told ABC News. "[The president] brought up how important information sharing is [and] by addressing critical infrastructure, he took care of another hurdle that we do not have to deal with."

Addressing privacy roadblocks, CISPA backers said the sharing of private customer information with the government, as long as personal details are stripped, is not unprecedented.

"Think of what we do with HIPAA in the medical professions; [doctors do not need to know] the individual person, just the symptoms to diagnose a disease," Michigan Gov. John Engler testified at a House Intelligence Committee hearing in an attempt to put the problem into context.

Read More..